APO Research
Talk to an analyst

APO RESEARCH · REPORT

Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032

28 December 2025120 pages

Choose your research edition.

Industry ResearchFactor Xa Inhibitors Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Factor Xa Inhibitors Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Factor Xa Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Factor Xa Inhibitors include Chia Tai Tianqing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Cspc Ouyi Pharmaceutical, Qilu Pharmaceutical, Nanjing King-Friend Biochemical Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Shanghai Huilun Pharmaceutical and Hansoh Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Factor Xa Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Factor Xa Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Factor Xa Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Factor Xa Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Factor Xa Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Factor Xa Inhibitors Market by Company

Chia Tai Tianqing Pharmaceutical

Zhejiang Hisun Pharmaceutical

Cspc Ouyi Pharmaceutical

Qilu Pharmaceutical

Nanjing King-Friend Biochemical Pharmaceutical

Kelun Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Shanghai Huilun Pharmaceutical

Hansoh Pharma

HEC Pharma

BrightGene

Zydus

Viatris

Pfizer

Lupin

Janssen Pharmaceuticals

GlaxoSmithKline

Eugia Pharma

Dr. Reddy's Laboratories

Daiichi Sankyo

Bristol Myers Squibb

Bayer

Apotex

Accord Healthcare

Factor Xa Inhibitors Segment by Type

Oral Drugs

Injections

Factor Xa Inhibitors Segment by Application

Atrial Fibrillation

Deep Vein Thrombosis

Pulmonary Embolism

Other

Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Factor Xa Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Drugs Table 2. Major Company of Injections Table 3. Global Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 5. Global Factor Xa Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 6. Global Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 7. Global Factor Xa Inhibitors Sales Market Share in Value by Type (2021-2026) Table 8. Global Factor Xa Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 9. Global Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 10. Global Factor Xa Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 11. Global Factor Xa Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 12. Global Factor Xa Inhibitors Sales Market Share in Value by Type (2027-2032) Table 13. Global Factor Xa Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 14. North America Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 15. North America Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 17. Europe Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Latin America Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Factor Xa Inhibitors Industry Trends Table 25. Factor Xa Inhibitors Industry Drivers Table 26. Factor Xa Inhibitors Industry Opportunities and Challenges Table 27. Factor Xa Inhibitors Industry Restraints Table 28. Global Factor Xa Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Factor Xa Inhibitors Revenue Market Share by Company (2021-2026) Table 30. Global Factor Xa Inhibitors Sales by Company (2021-2026) & (K Units) Table 31. Global Factor Xa Inhibitors Sales Share by Company (2021-2026) Table 32. Global Factor Xa Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Factor Xa Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Factor Xa Inhibitors Major Company Production Sites and Headquarters Table 35. Global Factor Xa Inhibitors Company, Product Type & Application Table 36. Global Factor Xa Inhibitors Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Factor Xa Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Factor Xa Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 41. Global Factor Xa Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 42. Global Factor Xa Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 43. Global Factor Xa Inhibitors Sales Market Share in Value by Region (2021-2026) Table 44. Global Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 46. Global Factor Xa Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 47. Global Factor Xa Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 48. Global Factor Xa Inhibitors Sales Market Share in Value by Region (2027-2032) Table 49. Global Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 52. Global Factor Xa Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 53. Global Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 54. Global Factor Xa Inhibitors Sales Market Share in Value by Application (2021-2026) Table 55. Global Factor Xa Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 56. Global Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 57. Global Factor Xa Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 58. Global Factor Xa Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 59. Global Factor Xa Inhibitors Sales Market Share in Value by Application (2027-2032) Table 60. Global Factor Xa Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 61. North America Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 62. North America Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 64. Europe Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 68. Latin America Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Chia Tai Tianqing Pharmaceutical Company Information Table 72. Chia Tai Tianqing Pharmaceutical Business Overview Table 73. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 75. Chia Tai Tianqing Pharmaceutical Recent Development Table 76. Zhejiang Hisun Pharmaceutical Company Information Table 77. Zhejiang Hisun Pharmaceutical Business Overview Table 78. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 80. Zhejiang Hisun Pharmaceutical Recent Development Table 81. Cspc Ouyi Pharmaceutical Company Information Table 82. Cspc Ouyi Pharmaceutical Business Overview Table 83. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 85. Cspc Ouyi Pharmaceutical Recent Development Table 86. Qilu Pharmaceutical Company Information Table 87. Qilu Pharmaceutical Business Overview Table 88. Qilu Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 90. Qilu Pharmaceutical Recent Development Table 91. Nanjing King-Friend Biochemical Pharmaceutical Company Information Table 92. Nanjing King-Friend Biochemical Pharmaceutical Business Overview Table 93. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 95. Nanjing King-Friend Biochemical Pharmaceutical Recent Development Table 96. Kelun Pharmaceutical Company Information Table 97. Kelun Pharmaceutical Business Overview Table 98. Kelun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 100. Kelun Pharmaceutical Recent Development Table 101. Jiangsu Hengrui Pharmaceuticals Company Information Table 102. Jiangsu Hengrui Pharmaceuticals Business Overview Table 103. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio Table 105. Jiangsu Hengrui Pharmaceuticals Recent Development Table 106. Shanghai Huilun Pharmaceutical Company Information Table 107. Shanghai Huilun Pharmaceutical Business Overview Table 108. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 110. Shanghai Huilun Pharmaceutical Recent Development Table 111. Hansoh Pharma Company Information Table 112. Hansoh Pharma Business Overview Table 113. Hansoh Pharma Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Hansoh Pharma Factor Xa Inhibitors Product Portfolio Table 115. Hansoh Pharma Recent Development Table 116. HEC Pharma Company Information Table 117. HEC Pharma Business Overview Table 118. HEC Pharma Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. HEC Pharma Factor Xa Inhibitors Product Portfolio Table 120. HEC Pharma Recent Development Table 121. BrightGene Company Information Table 122. BrightGene Business Overview Table 123. BrightGene Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. BrightGene Factor Xa Inhibitors Product Portfolio Table 125. BrightGene Recent Development Table 126. Zydus Company Information Table 127. Zydus Business Overview Table 128. Zydus Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Zydus Factor Xa Inhibitors Product Portfolio Table 130. Zydus Recent Development Table 131. Viatris Company Information Table 132. Viatris Business Overview Table 133. Viatris Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Viatris Factor Xa Inhibitors Product Portfolio Table 135. Viatris Recent Development Table 136. Pfizer Company Information Table 137. Pfizer Business Overview Table 138. Pfizer Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Pfizer Factor Xa Inhibitors Product Portfolio Table 140. Pfizer Recent Development Table 141. Lupin Company Information Table 142. Lupin Business Overview Table 143. Lupin Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Lupin Factor Xa Inhibitors Product Portfolio Table 145. Lupin Recent Development Table 146. Janssen Pharmaceuticals Company Information Table 147. Janssen Pharmaceuticals Business Overview Table 148. Janssen Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio Table 150. Janssen Pharmaceuticals Recent Development Table 151. GlaxoSmithKline Company Information Table 152. GlaxoSmithKline Business Overview Table 153. GlaxoSmithKline Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. GlaxoSmithKline Factor Xa Inhibitors Product Portfolio Table 155. GlaxoSmithKline Recent Development Table 156. Eugia Pharma Company Information Table 157. Eugia Pharma Business Overview Table 158. Eugia Pharma Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Eugia Pharma Factor Xa Inhibitors Product Portfolio Table 160. Eugia Pharma Recent Development Table 161. Dr. Reddy's Laboratories Company Information Table 162. Dr. Reddy's Laboratories Business Overview Table 163. Dr. Reddy's Laboratories Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio Table 165. Dr. Reddy's Laboratories Recent Development Table 166. Daiichi Sankyo Company Information Table 167. Daiichi Sankyo Business Overview Table 168. Daiichi Sankyo Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Daiichi Sankyo Factor Xa Inhibitors Product Portfolio Table 170. Daiichi Sankyo Recent Development Table 171. Bristol Myers Squibb Company Information Table 172. Bristol Myers Squibb Business Overview Table 173. Bristol Myers Squibb Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio Table 175. Bristol Myers Squibb Recent Development Table 176. Bayer Company Information Table 177. Bayer Business Overview Table 178. Bayer Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Bayer Factor Xa Inhibitors Product Portfolio Table 180. Bayer Recent Development Table 181. Apotex Company Information Table 182. Apotex Business Overview Table 183. Apotex Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Apotex Factor Xa Inhibitors Product Portfolio Table 185. Apotex Recent Development Table 186. Accord Healthcare Company Information Table 187. Accord Healthcare Business Overview Table 188. Accord Healthcare Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 189. Accord Healthcare Factor Xa Inhibitors Product Portfolio Table 190. Accord Healthcare Recent Development Table 191. North America Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. North America Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 193. North America Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 194. North America Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 195. North America Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 196. North America Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. North America Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 198. North America Factor Xa Inhibitors Market Share by Country (2021-2026) Table 199. North America Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. North America Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 201. Europe Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 202. Europe Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 203. Europe Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 204. Europe Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 205. Europe Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 206. Europe Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Europe Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 208. Europe Factor Xa Inhibitors Market Share by Country (2021-2026) Table 209. Europe Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Europe Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 211. Asia-Pacific Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 212. Asia-Pacific Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 213. Asia-Pacific Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 214. Asia-Pacific Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 215. Asia-Pacific Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 216. Asia-Pacific Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 217. Asia-Pacific Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 218. Asia-Pacific Factor Xa Inhibitors Market Share by Country (2021-2026) Table 219. Asia-Pacific Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 220. Asia-Pacific Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 221. Latin America Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 222. Latin America Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 223. Latin America Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 224. Latin America Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 225. Latin America Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 226. Latin America Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 227. Latin America Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 228. Latin America Factor Xa Inhibitors Market Share by Country (2021-2026) Table 229. Latin America Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 230. Latin America Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 231. Middle East and Africa Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 232. Middle East and Africa Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 233. Middle East and Africa Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 234. Middle East and Africa Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 235. Middle East and Africa Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 236. Middle East and Africa Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 237. Middle East and Africa Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 238. Middle East and Africa Factor Xa Inhibitors Market Share by Country (2021-2026) Table 239. Middle East and Africa Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 240. Middle East and Africa Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 241. Key Raw Materials Table 242. Raw Materials Key Suppliers Table 243. Factor Xa Inhibitors Distributors List Table 244. Factor Xa Inhibitors Customers List Table 245. Research Programs/Design for This Report Table 246. Authors List of This Report Table 247. Secondary Sources Table 248. Primary Sources List of Figures Figure 1. Factor Xa Inhibitors Image Figure 2. Global Factor Xa Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Factor Xa Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 5. Oral Drugs Image Figure 6. Global Oral Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Injections Image Figure 8. Global Injections Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Factor Xa Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Factor Xa Inhibitors Market Share by Type 2025 VS 2032 Figure 11. North America Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 12. North America Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 13. Europe Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 14. Europe Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Latin America Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Factor Xa Inhibitors Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Atrial Fibrillation Image Figure 24. Global Atrial Fibrillation Sales YoY Growth (2021-2032) & (K Units) Figure 25. Deep Vein Thrombosis Image Figure 26. Global Deep Vein Thrombosis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Pulmonary Embolism Image Figure 28. Global Pulmonary Embolism Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Factor Xa Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Factor Xa Inhibitors Market Share by Application 2025 VS 2032 Figure 33. North America Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 34. North America Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 35. Europe Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. Europe Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Latin America Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. North America Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Factor Xa Inhibitors Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Factor Xa Inhibitors Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Nanjing King-Friend Biochemical Pharmaceutical
  • Kelun Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Shanghai Huilun Pharmaceutical
  • Hansoh Pharma
  • HEC Pharma
  • BrightGene
  • Zydus
  • Viatris
  • Pfizer
  • Lupin
  • Janssen Pharmaceuticals
  • GlaxoSmithKline
  • Eugia Pharma
  • Dr. Reddy's Laboratories
  • Daiichi Sankyo
  • Bristol Myers Squibb
  • Bayer
  • Apotex
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Factor Xa Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Factor Xa Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Factor Xa Inhibitors Market by Type
  6. 1.3.1 Oral Drugs
  7. 1.3.2 Injections
  8. 1.4 Global Factor Xa Inhibitors Market Size by Type
  9. 1.4.1 Global Factor Xa Inhibitors Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Factor Xa Inhibitors Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Factor Xa Inhibitors Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Factor Xa Inhibitors Industry Trends
  2. 2.2 Factor Xa Inhibitors Industry Drivers
  3. 2.3 Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Factor Xa Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Factor Xa Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by Factor Xa Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by Factor Xa Inhibitors Price (2021-2026)
  4. 3.4 Global Factor Xa Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Factor Xa Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global Factor Xa Inhibitors Company, Product Type & Application
  7. 3.7 Global Factor Xa Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Factor Xa Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Factor Xa Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3
4 Factor Xa Inhibitors Regional Status and Outlook
  1. 4.1 Global Factor Xa Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Factor Xa Inhibitors Historic Market Size by Region
  3. 4.2.1 Global Factor Xa Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Factor Xa Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Factor Xa Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Factor Xa Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global Factor Xa Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Factor Xa Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Factor Xa Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Factor Xa Inhibitors by Application
  1. 5.1 Factor Xa Inhibitors Market by Application
  2. 5.1.1 Atrial Fibrillation
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Pulmonary Embolism
  5. 5.1.4 Other
  6. 5.2 Global Factor Xa Inhibitors Market Size by Application
  7. 5.2.1 Global Factor Xa Inhibitors Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Factor Xa Inhibitors Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Factor Xa Inhibitors Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chia Tai Tianqing Pharmaceutical
  2. 6.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 6.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 6.1.3 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio
  6. 6.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 6.2 Zhejiang Hisun Pharmaceutical
  8. 6.2.1 Zhejiang Hisun Pharmaceutical Company Information
  9. 6.2.2 Zhejiang Hisun Pharmaceutical Business Overview
  10. 6.2.3 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  12. 6.2.5 Zhejiang Hisun Pharmaceutical Recent Developments
  13. 6.3 Cspc Ouyi Pharmaceutical
  14. 6.3.1 Cspc Ouyi Pharmaceutical Company Information
  15. 6.3.2 Cspc Ouyi Pharmaceutical Business Overview
  16. 6.3.3 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio
  18. 6.3.5 Cspc Ouyi Pharmaceutical Recent Developments
  19. 6.4 Qilu Pharmaceutical
  20. 6.4.1 Qilu Pharmaceutical Company Information
  21. 6.4.2 Qilu Pharmaceutical Business Overview
  22. 6.4.3 Qilu Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio
  24. 6.4.5 Qilu Pharmaceutical Recent Developments
  25. 6.5 Nanjing King-Friend Biochemical Pharmaceutical
  26. 6.5.1 Nanjing King-Friend Biochemical Pharmaceutical Company Information
  27. 6.5.2 Nanjing King-Friend Biochemical Pharmaceutical Business Overview
  28. 6.5.3 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio
  30. 6.5.5 Nanjing King-Friend Biochemical Pharmaceutical Recent Developments
  31. 6.6 Kelun Pharmaceutical
  32. 6.6.1 Kelun Pharmaceutical Company Information
  33. 6.6.2 Kelun Pharmaceutical Business Overview
  34. 6.6.3 Kelun Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  36. 6.6.5 Kelun Pharmaceutical Recent Developments
  37. 6.7 Jiangsu Hengrui Pharmaceuticals
  38. 6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 6.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 6.7.3 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio
  42. 6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 6.8 Shanghai Huilun Pharmaceutical
  44. 6.8.1 Shanghai Huilun Pharmaceutical Company Information
  45. 6.8.2 Shanghai Huilun Pharmaceutical Business Overview
  46. 6.8.3 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  48. 6.8.5 Shanghai Huilun Pharmaceutical Recent Developments
  49. 6.9 Hansoh Pharma
  50. 6.9.1 Hansoh Pharma Company Information
  51. 6.9.2 Hansoh Pharma Business Overview
  52. 6.9.3 Hansoh Pharma Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Hansoh Pharma Factor Xa Inhibitors Product Portfolio
  54. 6.9.5 Hansoh Pharma Recent Developments
  55. 6.10 HEC Pharma
  56. 6.10.1 HEC Pharma Company Information
  57. 6.10.2 HEC Pharma Business Overview
  58. 6.10.3 HEC Pharma Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 HEC Pharma Factor Xa Inhibitors Product Portfolio
  60. 6.10.5 HEC Pharma Recent Developments
  61. 6.11 BrightGene
  62. 6.11.1 BrightGene Company Information
  63. 6.11.2 BrightGene Business Overview
  64. 6.11.3 BrightGene Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 BrightGene Factor Xa Inhibitors Product Portfolio
  66. 6.11.5 BrightGene Recent Developments
  67. 6.12 Zydus
  68. 6.12.1 Zydus Company Information
  69. 6.12.2 Zydus Business Overview
  70. 6.12.3 Zydus Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Zydus Factor Xa Inhibitors Product Portfolio
  72. 6.12.5 Zydus Recent Developments
  73. 6.13 Viatris
  74. 6.13.1 Viatris Company Information
  75. 6.13.2 Viatris Business Overview
  76. 6.13.3 Viatris Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Viatris Factor Xa Inhibitors Product Portfolio
  78. 6.13.5 Viatris Recent Developments
  79. 6.14 Pfizer
  80. 6.14.1 Pfizer Company Information
  81. 6.14.2 Pfizer Business Overview
  82. 6.14.3 Pfizer Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Pfizer Factor Xa Inhibitors Product Portfolio
  84. 6.14.5 Pfizer Recent Developments
  85. 6.15 Lupin
  86. 6.15.1 Lupin Company Information
  87. 6.15.2 Lupin Business Overview
  88. 6.15.3 Lupin Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Lupin Factor Xa Inhibitors Product Portfolio
  90. 6.15.5 Lupin Recent Developments
  91. 6.16 Janssen Pharmaceuticals
  92. 6.16.1 Janssen Pharmaceuticals Company Information
  93. 6.16.2 Janssen Pharmaceuticals Business Overview
  94. 6.16.3 Janssen Pharmaceuticals Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio
  96. 6.16.5 Janssen Pharmaceuticals Recent Developments
  97. 6.17 GlaxoSmithKline
  98. 6.17.1 GlaxoSmithKline Company Information
  99. 6.17.2 GlaxoSmithKline Business Overview
  100. 6.17.3 GlaxoSmithKline Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 GlaxoSmithKline Factor Xa Inhibitors Product Portfolio
  102. 6.17.5 GlaxoSmithKline Recent Developments
  103. 6.18 Eugia Pharma
  104. 6.18.1 Eugia Pharma Company Information
  105. 6.18.2 Eugia Pharma Business Overview
  106. 6.18.3 Eugia Pharma Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Eugia Pharma Factor Xa Inhibitors Product Portfolio
  108. 6.18.5 Eugia Pharma Recent Developments
  109. 6.19 Dr. Reddy's Laboratories
  110. 6.19.1 Dr. Reddy's Laboratories Company Information
  111. 6.19.2 Dr. Reddy's Laboratories Business Overview
  112. 6.19.3 Dr. Reddy's Laboratories Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio
  114. 6.19.5 Dr. Reddy's Laboratories Recent Developments
  115. 6.20 Daiichi Sankyo
  116. 6.20.1 Daiichi Sankyo Company Information
  117. 6.20.2 Daiichi Sankyo Business Overview
  118. 6.20.3 Daiichi Sankyo Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Daiichi Sankyo Factor Xa Inhibitors Product Portfolio
  120. 6.20.5 Daiichi Sankyo Recent Developments
  121. 6.21 Bristol Myers Squibb
  122. 6.21.1 Bristol Myers Squibb Company Information
  123. 6.21.2 Bristol Myers Squibb Business Overview
  124. 6.21.3 Bristol Myers Squibb Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio
  126. 6.21.5 Bristol Myers Squibb Recent Developments
  127. 6.22 Bayer
  128. 6.22.1 Bayer Company Information
  129. 6.22.2 Bayer Business Overview
  130. 6.22.3 Bayer Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Bayer Factor Xa Inhibitors Product Portfolio
  132. 6.22.5 Bayer Recent Developments
  133. 6.23 Apotex
  134. 6.23.1 Apotex Company Information
  135. 6.23.2 Apotex Business Overview
  136. 6.23.3 Apotex Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Apotex Factor Xa Inhibitors Product Portfolio
  138. 6.23.5 Apotex Recent Developments
  139. 6.24 Accord Healthcare
  140. 6.24.1 Accord Healthcare Company Information
  141. 6.24.2 Accord Healthcare Business Overview
  142. 6.24.3 Accord Healthcare Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Accord Healthcare Factor Xa Inhibitors Product Portfolio
  144. 6.24.5 Accord Healthcare Recent Developments
7 North America by Country
  1. 7.1 North America Factor Xa Inhibitors Sales by Country
  2. 7.1.1 North America Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America Factor Xa Inhibitors Market Size by Country
  6. 7.2.1 North America Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Factor Xa Inhibitors Sales by Country
  2. 8.1.1 Europe Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Factor Xa Inhibitors Market Size by Country
  6. 8.2.1 Europe Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Factor Xa Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Factor Xa Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Factor Xa Inhibitors Sales by Country
  2. 10.1.1 South America Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America Factor Xa Inhibitors Market Size by Country
  6. 10.2.1 South America Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Factor Xa Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Factor Xa Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Factor Xa Inhibitors Value Chain Analysis
  2. 12.1.1 Factor Xa Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Factor Xa Inhibitors Production Mode & Process
  7. 12.2 Factor Xa Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Factor Xa Inhibitors Distributors
  10. 12.2.3 Factor Xa Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst